首页> 中文期刊> 《中国继续医学教育》 >枯草杆菌二联活菌胶囊联合三联疗法根除幽门螺杆菌感染临床对照研究

枯草杆菌二联活菌胶囊联合三联疗法根除幽门螺杆菌感染临床对照研究

             

摘要

Objective To observe the clinical control study of the combination of Bacillus subtilis two live bacteria capsule and triple therapy in the eradication of Helicobacter pylori infection. Methods 91 cases in helicobacter pylori positive patients were divided to three groups, the treatment group 1 to give ray sodium rabeprazole, amoxicillin, levofloxacin in the treatment of treatment group 2 give bacillus subtilis enterococcus second combined live bacterial capsule and ray sodium rabeprazole, amoxi, levofloxacin in the treatment, the controls give ray sodium rabeprazole, amoxicillin, levofloxacin in the treatment of treatment 14 days compared clinical effect and adverse reaction of situation. Results 3 groups of eradication rates were 86.7%, 93.3% and 64.5%, the treatment group were higher than control group (P<0.05), the curative effect, the treatment group and the control group had no significant difference (P>0.05), the rate of adverse reaction in the two groups treated with (3%) lower in the treatment group 1 (26.7%) and control group (22.5%) (P<0.05). Conclusion Probiotics combined with triple therapy can improve the Helicobacter pylori eradication rate, patients with less adverse reactions.%目的:观察枯草杆菌二联活菌胶囊联合三联疗法在根除幽门螺杆菌感染患者的临床对照研究。方法将91例H.pylori 阳性患者随机分为,治疗1组(30例),给予三联疗法(雷贝拉唑钠、阿莫西林、左氧氟沙星)治疗,治疗2组(30例),给予枯草杆菌肠球菌二联活菌胶囊联合三联疗法治疗,对照组(31例),治疗同治疗1组,但雷贝拉唑钠剂量减半,均治疗14 d,比较临床效果及不良反应情况。结果3组根除率分别为86.7%、93.3%、64.5%,2个治疗组高于对照组(P<0.05);在疗效上,2个治疗组与对照组对比,无明显统计学差异(P >0.05);治疗2组不良反应率3%,低于治疗1组26.7%及对照组22.5%(P <0.05)。结论益生菌联合三联疗法能明显提高 H. pylori 根除率及症状缓解率;同时减少药物不良反应,提高药物安全性,增加患者依从性。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号